Cara Therapeutics, Inc. ( NASDAQ:CARA – Get Free Report ) has been given an average recommendation of 'Moderate Buy' by the six ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $17.00. CARA has been the topic of a number of research reports.

https://www.dailypolitical.com/2023/10/08/analysts-set-cara-therapeutics-inc-nasdaqcara-target-price-at-17-00.html

#dailypolitical